The U.S. Chinese Anti-Cancer Association (USCACA) and AFCR are pleased to invite nominations for the USCACA‐AFCR 2024 Young Investigator Awards. The Awards will recognize 3 to 5 junior Chinese investigators on the basis of significant contributions in Translational or Clinical Cancer Research. Candidacy is open to all junior Chinese faculty who…...
Join Us for Our Inaugural Day of Giving!
On 14 June 2024, AFCR is launching our inaugural Day of Giving. This special event aims to spotlight the critical “unmet needs in cancer research and patient care.” By generously supporting AFCR, you empower us to drive groundbreaking discoveries in the fight against cancer. Why Support AFCR? AFCR is committed…...
Asian Fund for Cancer Research (AFCR) commends Dr. Yung-Chi Cheng’s three decades of pioneering research and celebrates Yiviva’s recent partnership with AstraZeneca China
The Asian Fund for Cancer Research (AFCR) proudly recognizes the exceptional contributions of Dr. Yung-Chi Cheng, AFCR Scientific Advisory Board Member, and Henry Bronson Professor of Pharmacology and Medicine at Yale University. Dr. Cheng’s unwavering commitment over the past thirty years has led to the establishment of Yiviva, a clinical-stage…...
Join us on World Cancer Day!
Did you know that there were 9.5 million newly reported cancer cases and 5.8 million cancer-related deaths occurring in Asia in 2020? These numbers are devastating! Even worse, without intervention, the number of new cases in Asia is anticipated to increase to 10.6 million in 2023. We must act to…...
Asian Fund for Cancer Research Announces Degron Therapeutics as the 2023 BRACE Award Venture Competition Winner
HONG KONG – The Asian Fund for Cancer Research (AFCR) is pleased to announce that Degron Therapeutics was selected as the winner of the 2023 BRACE Award Venture Competition. AFCR’s BRACE (Bridging Research from Academia to Cancer Entrepreneurship) Award Venture Competition is designed to support and accelerate oncology innovations on…...
Asian Fund for Cancer Research Limited Unveils Inspiring New Logo and Slogan, signifying a Global Commitment to Advancing Cancer Research – from Asia to the World.
The Asian Fund for Cancer Research (AFCR) is thrilled to unveil its fresh brand logo and slogan, marking a pivotal moment in the organization’s quest to advance breakthroughs in cancer globally. The redesigned emblem and impactful slogan firmly establish AFCR as a prominent voice in the ongoing battle against cancer,…...
The Asian Fund for Cancer Research and the US Chinese Anti-Cancer Association Recognize Young Chinese Cancer Researchers with the 2023 Young Investigator Awards
Left to right: Prof. Shi-Yong Sun, Prof. Tianzhi Huang, Prof. Lirong Zhang, Prof. Ming Yan, Prof. Qi Zhang, Prof. Yunguang Tong, Prof. Song Xu, Prof. Binghua Jiang, Prof. Xu Qian, Prof. Zigang Dong. To foster and strengthen collaborations among cancer researchers and physicians in the United States and China, the…...
AFCR CEO & Founder Dr. Sujuan Ba has been awarded the Inaugural Leadership Award for Global Advocate of Cancer Research at BIOHK2023
Sujuan Ba, Ph.D. has been awarded the Leadership Award for Global Advocate of Cancer Research by the Hong Kong Biotechnology Organization (HKBIO) at their BIOHK2023 Conference (13-16 September, Hong Kong Convention and Exhibition Centre). Dr. Ba is the President, CEO and Founder of the Asian Fund for Cancer Research, CEO…...
CityU and Asian Fund for Cancer Research sign MoU to boost biomedical innovation
Professor Michael Yang Mengsu, Senior Vice-President (Innovation and Enterprise) of CityU (second from right) and Dr Sujuan Ba (second from left) signed the MoU, witnessed by Mr Lester Garson Huang, Council Chairman of CityU (first from right), and Ms Lillian Cheong, Under Secretary for Innovation, Technology and Industry, HKSAR Government…...
USCACA – AFCR 2023 Young Investigator Awards
The U.S. Chinese Anti-Cancer Association (USCACA) and AFCR are pleased to invite nominations for the USCACA-‐AFCR 2023 Young Investigator Awards. The Awards will recognize 3 to 5 junior Chinese investigators on the basis of significant contributions in Translational or Clinical Cancer Research. Candidacy is open to all Chinese researchers who…...
